As on Thursday, Immunome Inc (NASDAQ: IMNM) got off with the flyer as it spiked 10.07% to $22.85, before settling in for the price of $20.76 at the close. Taking a more long-term approach, IMNM posted a 52-week range of $5.15-$25.30.
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -38.15%. Meanwhile, its Annual Earning per share during the time was -38.15%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 55.23%. This publicly-traded company’s shares outstanding now amounts to $110.33 million, simultaneously with a float of $99.36 million. The organization now has a market capitalization sitting at $2.52 billion.
Immunome Inc (IMNM) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Immunome Inc’s current insider ownership accounts for 9.94%, in contrast to 80.26% institutional ownership. According to the most recent insider trade that took place on Dec 30 ’25, this organization’s President and CEO bought 4,729 shares at the rate of 21.15, making the entire transaction reach 100,018 in total value, affecting insider ownership by 665,254. Preceding that transaction, on Dec 22 ’25, Company’s Director sold 383,200 for 21.74, making the whole transaction’s value amount to 8,330,080. This particular insider is now the holder of 2,031,181 in total.
Immunome Inc (IMNM) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.56 per share during the current fiscal year.
Immunome Inc’s EPS increase for this current 12-month fiscal period is 55.23% and is forecasted to reach -2.59 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 22.53% through the next 5 years, which can be compared against the -38.15% growth it accomplished over the previous five years trading on the market.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
Let’s observe the current performance indicators for Immunome Inc (IMNM). It’s Quick Ratio in the last reported quarter now stands at 8.90. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 260.45.
In the same vein, IMNM’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.96, a figure that is expected to reach -0.59 in the next quarter, and analysts are predicting that it will be -2.59 at the market close of one year from today.
